Armin Hatzelmann

This inventor holds 20 USPTO granted patents and 5 published patent applications and 14 EPO patents. Top assignees: Bayer Aktiengesellschaft, Takeda Gmbh, Nycomed Gmbh. Active years: 1993-2016.

USPTO Granted Patents = 20 (Patent Applications = 5)

% Patents Active = 55.0

EPO Patents = 14 (Patent Applications = 10)

Average Co-Inventor Count = 7.3

ph-index = 4

Forward Citations = 44(Granted Patents)

Location History:

Konstanz, DE (1993 - 1994)
Burscheid, DE (1993 - 1995)
Constance, DE (1994 - 2016)

Company Filing History:

9 out of 12,266

Bayer Aktiengesellschaft

Byk Gulden Lomberg Chemische Fabrik Gmbh

patents

Years Active: 1993-2016

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9340522 - Pyrazolone-derivatives and their use as PDE-4 inhibitors (2016-05-17),

2. 9090597 - Pyrazolone derivatives as PDE4 inhibitors (2015-07-28),

3. 9018175 - 3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives (2015-04-28),

4. 8865745 - Pyrazolone derivatives as PDE4 inhibitors (2014-10-21),

5. 8648100 - Roflumilast for the treatment of pulmonary hypertension (2014-02-11),

6. 8609848 - Pyrazolone-derivatives and their use as PDE-4 inhibitors (2013-12-17),

7. 8304436 - Pyrazolone derivatives as PDE4 inhibitors (2012-11-06),

8. 7838521 - 3-oxa-10-aza-phenanthrenes (2010-11-23),

9. 7589205 - 3-thia-10-aza-phenanthrene derivatives (2009-09-15),

10. 6818651 - (Dihydro) isoquinoline derivatives as phosphodiesterase inhibitors (2004-11-16),

11. 6384047 - Benzonaphthyridine (2002-05-07),

12. 5597833 - Substituted quinol-2-yl-methoxy-phenylacetic acid derivatives (1997-01-28),

13. 5399698 - Quinolin-2-yl-methoxybenzylhydroxyureas (1995-03-21),

14. 5310744 - Quinolylmethoxyphenyl-acetamides (1994-05-10),

15. 5304563 - 2-substituted quinolines, and their use in medicaments (1994-04-19),

Title: The Innovative Journey of Armin Hatzelmann

Introduction: Armin Hatzelmann, based in Constance, Germany, is a prominent inventor known for his contributions to the pharmaceutical industry. With a total of 20 patents to his name, Hatzelmann's work focuses on innovative compounds that address significant medical challenges.

Latest Patents: Among his latest innovations are two noteworthy patents involving Pyrazolone derivatives as inhibitors of type 4 phosphodiesterase (PDE-4). These compounds are recognized for their effectiveness in treating conditions such as psoriasis and atopic dermatitis. The detailed composition of one such invention is represented by the compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione, illustrating Hatzelmann's skill in developing novel therapeutic agents.

Career Highlights: Hatzelmann has made substantial contributions while working with renowned pharmaceutical companies like Bayer Aktiengesellschaft and Takeda GmbH. His career is marked by a series of innovations that have advanced the field of medicinal chemistry, most notably in the design and application of effective pharmaceutical compounds.

Collaborations: Throughout his career, Armin has collaborated with notable colleagues, including Siegfried Raddatz and Klaus-Helmut Mohrs. These partnerships have fostered a collaborative environment that has been instrumental in the successful development of his innovative inventions.

Conclusion: Armin Hatzelmann's work exemplifies the spirit of innovation within the pharmaceutical industry. His dedication to research and development, coupled with significant collaborations and a strong portfolio of patents, continues to make a lasting impact on medical treatments and therapies. His journey is a testament to the importance of creativity and collaboration in the pursuit of scientific advancements.